Osamu Okuda

Osamu Okuda serves as President and CEO of Chugai Pharmaceutical Co., Ltd., Japan's most research-intensive pharmaceutical company and the country's leader in innovative drug development. Chugai occupies a unique position: it is majority-owned (approximately 61%) by Roche, the Swiss pharmaceutical giant, creating a strategic alliance where Chugai develops and commercializes Roche's drugs in Japan while independently pursuing its own innovative pipeline. Chugai's competitive advantage lies in its antibody engineering capabilities, particularly its proprietary recycling antibody technology and bispecific antibody platforms. The company's research has produced breakthrough drugs including Hemlibra (emicizumab) for hemophilia A — a blockbuster that Roche markets globally and that generates substantial royalty income for Chugai. The company is also advancing a pipeline in oncology, rare diseases, and ophthalmology. Okuda's strategic decisions revolve around R&D pipeline prioritization, the balance between Roche-originated drugs and Chugai's own innovations, manufacturing capacity for biologics, and capital allocation. Chugai's unique Roche alliance structure means it benefits from global marketing of its innovations while having access to Roche's drug portfolio for Japan, creating a diversified revenue model. His leadership of Chugai's increasingly global research contribution — as Roche relies more on Chugai's antibody engineering — is the primary driver of the stock's premium valuation among Japanese pharma companies.